Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: Short-term results of a randomised study

British Journal of Ophthalmology

Volumn 92, Issue 10, 2008, Pages 1347-1351

  Sacu, S ^a   Varga, A ^a   Michels, S ^b   Weigert, G ^a   Polak, K ^a   Vecsei Marlovits P V ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

AGED; ARTICLE; BACKACHE; CHOROID; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 53649092795     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2008.137885     Document Type: Article

References (15)

1. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-41.
2. Schmidt-Erfurth U, Schlötzer-Schrebard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
3. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57.
4. Michels S, Hansmann F, Geitzenauer W, et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371-6.
5. Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
6. Zhang J, Quan H, Ng J, et al. Some statistical methods for multiple endpoints of clinical trials. Controlled Clin Trials 1997;18:204-21.
7. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
8. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53.
9. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52.
10. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7.
11. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-40.
12. Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-7.
13. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
14. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
15. Antoszyk AN, Tuomi L, Chung CY, Singh A, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-74.